Janux Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Janux Therapeutics, Inc. on June 14, 2022. The report details the results of the Company's 2022 Annual Meeting of Stockholders held on the same date. As of the record date of April 18, 2022, there were 41,629,367 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two primary proposals at the Annual Meeting:
- Proposal 1: Election of Directors - Stockholders elected three Class I directors to serve until the 2025 Annual Meeting.
- David Campbell, Ph.D.: 33,897,515 votes For; 958,663 votes Withheld.
- Ron Barrett, Ph.D.: 34,688,072 votes For; 168,106 votes Withheld.
- Stefan Heller, Ph.D.: 33,873,562 votes For; 982,616 votes Withheld.
- Proposal 2: Ratification of Independent Auditor - Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Votes For: 37,854,460
- Votes Against: 3
- Abstentions: 244
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that the three elected directors (Campbell, Barrett, Heller) have assumed their roles as Class I directors.
- Verification that Ernst & Young LLP has formally accepted the engagement for the 2022 fiscal year.
- Review of the Company's subsequent filings (e.g., 10-K or 10-Q) for financial performance data, as this 8-K contains no financial metrics.